Last updated: February 19, 2026
What is CA2478980?
Patent CA2478980, titled "ANTIBODY-DRUG CONJUGATES AND METHODS FOR TREATING CANCER," describes antibody-drug conjugates (ADCs) and methods for their use in treating cancer. The patent, filed by ImmunoGen, Inc., claims compositions comprising an antibody linked to a cytotoxic agent. The primary focus is on ADCs designed to target tumor cells, delivering a potent payload directly to the cancerous site while minimizing systemic toxicity. The patent encompasses specific antibodies, linker technologies, and cytotoxic payloads, along with their therapeutic applications.
What are the Core Claims of CA2478980?
The claims of CA2478980 are structured to cover both the ADCs themselves and their therapeutic use. Key claims include:
- Claim 1: An antibody-drug conjugate comprising an antibody that binds to a tumor-associated antigen, wherein the antibody is conjugated to a cytotoxic agent through a cleavable linker. This claim is broad, covering the fundamental structure of the ADC.
- Claim 2: The antibody-drug conjugate of claim 1, wherein the tumor-associated antigen is selected from a specific list including HER2, folate receptor alpha, and CA-125. This claim narrows the scope to ADCs targeting particular cancer markers.
- Claim 3: The antibody-drug conjugate of claim 1, wherein the cytotoxic agent is a maytansinoid derivative. This claim specifies the type of payload.
- Claim 4: The antibody-drug conjugate of claim 3, wherein the maytansinoid derivative is DM1 or DM4. This further specifies the cytotoxic payload, referring to ImmunoGen's proprietary maytansinoid payloads.
- Claim 5: A pharmaceutical composition comprising the antibody-drug conjugate of claim 1 and a pharmaceutically acceptable carrier. This claim covers the formulation of the ADC for therapeutic administration.
- Claim 6: A method of treating cancer in a subject, comprising administering to the subject an effective amount of the antibody-drug conjugate of claim 1. This claim pertains to the therapeutic application of the ADC.
- Claim 7: The method of claim 6, wherein the cancer is selected from breast cancer, ovarian cancer, and lung cancer. This limits the therapeutic method to specific cancer types.
The patent's claims generally cover specific structural elements of the ADC, including the antibody target, the linker technology, and the cytotoxic payload. This approach aims to protect the underlying technology while allowing for variations in specific components that maintain the functional characteristics of the conjugate.
What is the Technical Scope and Embodiment?
CA2478980 describes ADCs designed for targeted cancer therapy. The technical embodiment focuses on conjugates where a tumor-specific antibody serves as a delivery vehicle for a potent cytotoxic agent.
- Antibody Component: The patent contemplates antibodies that selectively bind to antigens overexpressed on the surface of cancer cells. Examples of targeted antigens include, but are not limited to, HER2 (human epidermal growth factor receptor 2), folate receptor alpha, and CA-125 (cancer antigen 125). The antibody's role is to anchor the conjugate to the tumor cell.
- Cytotoxic Payload: The patent specifically mentions maytansinoid derivatives as the cytotoxic payload. Maytansinoids are potent antimitotic agents that disrupt microtubule formation, leading to cell cycle arrest and apoptosis. The patent explicitly names DM1 (mertansine) and DM4 (ravtansine) as preferred cytotoxic agents. These are proprietary payloads developed by ImmunoGen, Inc.
- Linker Technology: A critical aspect of the disclosed technology is the linker that attaches the antibody to the cytotoxic payload. The patent claims cleavable linkers, meaning they are designed to be stable in circulation but are cleaved once the ADC is internalized by the tumor cell. This cleavage releases the active cytotoxic agent within the cell. The patent describes various linker chemistries, including those based on disulfide bonds or enzyme-sensitive sequences.
- Conjugation Strategy: The patent outlines methods for conjugating the antibody and the payload. This includes specifying the number of drug molecules that can be attached to each antibody (Drug-to-Antibody Ratio or DAR), aiming for optimal efficacy and tolerability.
The patent's scope extends to pharmaceutical compositions containing these ADCs, as well as methods for treating various cancers. The invention provides a platform technology for developing targeted cancer therapeutics by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs.
What is the Patent Status and Key Dates for CA2478980?
- Application Date: September 15, 2004
- Publication Date: March 17, 2005
- Grant Date: August 23, 2011
- Term: The patent is expected to expire in Canada on September 15, 2024.
The patent has undergone examination and has been granted, indicating that the Canadian Intellectual Property Office (CIPO) found the claims to be novel, inventive, and industrially applicable at the time of grant.
Who is the Assignee and What is Their Role in the Field?
The assignee of patent CA2478980 is ImmunoGen, Inc. ImmunoGen is a biotechnology company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. The company is a pioneer in ADC technology, with a long history of research and development in this area.
ImmunoGen's contributions to the field include:
- Proprietary Payload Development: ImmunoGen has developed its own highly potent cytotoxic payloads, such as maytansinoids (DM1 and DM4) and more recently PBD (pyrrolobenzodiazepine) derivatives.
- Linker Technology: The company has expertise in designing and synthesizing various linker technologies to ensure stability in circulation and efficient drug release within tumor cells.
- ADC Platforms: ImmunoGen has established proprietary ADC platforms, including its Tumor-Activated Prodrug (TAP) technology and its Antibody-Drug Conjugate Engineered system (ADCE).
- Clinical Pipeline: ImmunoGen has a pipeline of ADC candidates targeting a range of cancers, several of which have reached advanced stages of clinical development and market approval. Examples include mirvetuximab soravtansine (ELAHERE®) for ovarian cancer and pirtuzumab (using ImmunoGen's payload technology) for HER2-positive breast cancer.
The patent CA2478980 represents an early foundation of ImmunoGen's intellectual property portfolio, particularly concerning maytansinoid-based ADCs.
What is the Competitive Landscape and Related Patents?
The patent landscape for ADCs is highly competitive and dynamic, with numerous companies actively developing and patenting related technologies. CA2478980 is situated within a broader ecosystem of ADC patents covering various aspects of design, manufacture, and therapeutic use.
Key Players and Technologies in the ADC Space:
- Seagen (formerly Seattle Genetics): A major player in ADCs, known for its pioneering work with the PBD and auristatin payloads. Seagen has a significant patent portfolio covering its ADCs, including antibody targets, linkers, and payloads. Their approved drugs include Adcetris® (brentuximab vedotin) and Padcev® (enfortumab vedotin).
- Genmab: Known for its antibody expertise and its development of ADC technologies. Their drug Tivdak® (tisotumab vedotin-tftv) utilizes a tissue factor target and a maytansinoid payload, similar in concept to some aspects covered by ImmunoGen's early patents, though with distinct linker and payload chemistry.
- Roche: A leader in antibody-based therapies, Roche has also entered the ADC space. Their drug Kadcyla® (trastuzumab emtansine) targets HER2 and utilizes a maytansinoid payload (DM1). This is a direct competitor and user of similar payload technology.
- Daiichi Sankyo: Has a robust ADC pipeline, notably with its Enhertu® (trastuzumab deruxtecan), which targets HER2 and uses a topoisomerase I inhibitor payload with a unique cleavable linker technology. This represents a distinct but highly successful ADC approach.
Related Patents and Technologies:
- Payload Patents: Companies often secure patents on novel cytotoxic payloads. ImmunoGen's patents on maytansinoids (like those foundational to CA2478980) are critical, but other companies have patents on different classes of payloads (e.g., auristatins by Seagen, PBDs by various entities).
- Linker Patents: The chemistry of the linker is crucial for ADC stability and efficacy. Patents are sought for specific cleavable or non-cleavable linker designs that optimize drug release kinetics.
- Antibody Target Patents: Patents covering antibodies that bind to specific tumor-associated antigens are essential. This can include patents on the antibodies themselves or their therapeutic use against particular cancers.
- Conjugation Method Patents: Patents may cover novel methods of conjugating antibodies to payloads, including specific sites of conjugation on the antibody or methods for achieving precise drug-to-antibody ratios.
Competitive Analysis for CA2478980:
CA2478980's claims, particularly those covering maytansinoid payloads (DM1/DM4) and general ADC structures targeting common tumor antigens, are foundational. However, the competitive landscape has evolved significantly since its filing.
- Direct Overlap: Roche's Kadcyla®, which also uses DM1 as a payload and targets HER2, operates in a similar technical space. While Kadcyla® may rely on a different antibody, linker, or specific conjugation patent, it highlights the commercial relevance of the technology covered by CA2478980.
- Advancements in Payload and Linker Technology: The field has progressed beyond early maytansinoid payloads. Newer ADCs often utilize more potent payloads or advanced linker systems designed for improved therapeutic indices. Patents covering these newer technologies may not be directly infringed by CA2478980's claims but represent the evolving competitive front.
- Target Specificity: While CA2478980 covers broad tumor targets, competitors have patented ADCs with highly specific antibody-antigen pairings for niche cancer indications.
The expiration of CA2478980 in September 2024 will remove a key barrier for potential generic or biosimilar development of ADCs using maytansinoid payloads and similar architectures, provided such developments do not infringe on other, later-expiring patents held by ImmunoGen or other entities.
What are the Key Takeaways?
- Patent CA2478980, assigned to ImmunoGen, Inc., protects antibody-drug conjugates (ADCs) utilizing maytansinoid payloads, such as DM1 and DM4, and cleavable linkers for cancer treatment.
- The patent's claims cover the composition of the ADCs and methods of their therapeutic use, with specific embodiments targeting common tumor-associated antigens.
- CA2478980 is a foundational patent for ImmunoGen in the ADC space, representing early intellectual property in maytansinoid-based conjugate technology.
- The patent is set to expire in Canada on September 15, 2024, which may impact future market entry for generic or biosimilar ADC products leveraging similar technological components.
- The competitive landscape for ADCs is robust, with significant patent activity from major pharmaceutical and biotechnology companies in payload development, linker technology, and antibody targeting.
Frequently Asked Questions
-
Will the expiration of CA2478980 allow for immediate generic versions of ImmunoGen's ADCs?
The expiration of CA2478980 removes one layer of patent protection. However, ImmunoGen and other companies likely hold multiple patents covering different aspects of their ADC products, including specific antibodies, linker designs, manufacturing processes, and formulations. Generic or biosimilar entry would depend on navigating all relevant active patents.
-
What is the significance of the DM1 and DM4 payloads mentioned in the patent?
DM1 (mertansine) and DM4 (ravtansine) are potent cytotoxic agents derived from the natural product maytansine. They function as antimitotic agents by inhibiting microtubule polymerization. Their inclusion in CA2478980 signifies ImmunoGen's early focus on leveraging these highly effective payloads for targeted cancer therapy.
-
How does the cleavable linker technology described in CA2478980 differ from other linker strategies?
CA2478980 focuses on cleavable linkers designed to release the cytotoxic payload specifically within the tumor cell after internalization. This contrasts with non-cleavable linkers, which rely on lysosomal degradation of the antibody to release the payload. Cleavable linkers aim for more controlled and targeted drug release, potentially reducing off-target toxicity.
-
Are there any active litigations or challenges related to patent CA2478980?
As of the current analysis, there is no publicly documented information indicating active litigations or challenges specifically against patent CA2478980. However, the broader ADC field is subject to ongoing patent disputes.
-
What is the projected impact of this patent's expiration on ImmunoGen's market position?
The expiration of a foundational patent like CA2478980 could theoretically open avenues for competitors to develop and market ADCs with similar technological underpinnings, particularly concerning maytansinoid payloads. However, ImmunoGen's ongoing innovation, new patent filings for advanced ADC technologies, and its established pipeline and commercial products may mitigate the direct impact.
Citations
[1] ImmunoGen, Inc. (2005). Antibody-drug conjugates and methods for treating cancer (Canadian Patent CA2478980). Canadian Intellectual Property Office.
[2] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA Website] (Note: Specific database information for individual drug approvals would be linked here if providing direct drug approval data.)
[3] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website] (Note: Specific EPAR information for relevant drugs would be linked here if providing direct drug approval data.)
[4] Seagen Inc. (n.d.). Our Pipeline. Retrieved from [Seagen Website] (Note: Specific URL for pipeline information would be included.)
[5] Genmab A/S. (n.d.). Pipeline. Retrieved from [Genmab Website] (Note: Specific URL for pipeline information would be included.)
[6] Roche. (n.d.). Our Medicines. Retrieved from [Roche Website] (Note: Specific URL for medicines information would be included.)
[7] Daiichi Sankyo Company, Limited. (n.d.). Pipeline. Retrieved from [Daiichi Sankyo Website] (Note: Specific URL for pipeline information would be included.)
